Status:
ENROLLING_BY_INVITATION
Investigating How Childhood Tumours and Congenital Disease Develop
Lead Sponsor:
The Wellcome Sanger Institute
Conditions:
Childhood Tumor
Congenital Disorders
Eligibility:
All Genders
Brief Summary
Every cell and every organ in the human body derives from a fertilised egg. As the fertilised egg divides, a human being develops and grows. The process of how the fertilised egg divides and forms a h...
Detailed Description
Cancers and some congenital anomalies are caused by changes (mutations) in the genetic code (DNA) of cells. The use of Next Generation Sequencing (NGS) has enabled the study of the genetic changes tha...
Eligibility Criteria
Inclusion
- Presence of childhood tumour / congenital disease, or relative of participant with childhood tumour / congenital disease
- Sufficient \'surplus to diagnostic/clinical use\' tissue is available
- Child assent and parental/guardian consent obtained where applicable
Exclusion
- Insufficient surplus tissue is available
Key Trial Info
Start Date :
February 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2026
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT06584877
Start Date
February 2 2017
End Date
February 28 2026
Last Update
September 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wellcome Sanger Institute
Cambridge, United Kingdom